Table 4 |
||||
|
Changes in different variables between 3 and 24 months, using a mixed linear model |
||||
|
P value |
||||
|
|
||||
|
Treatment A (n = 14) |
Treatment B (n = 11) |
Time |
Treatment × Compliance × Time |
|
|
|
||||
|
DAS28 |
-1.8 (-2.6 to -1.0) |
-1.9 (-2.8 to -1.0) |
<0.001 |
0.59 |
|
ESRa |
-0.62 (-1.07 to -0.18) |
-0.49 (-0.99 to 0.02) |
0.003 |
0.78 |
|
HAQ |
-0.27 (-0.50 to -0.04) |
-0.43 (-0.69 to -0.17) |
<0.001 |
0.82 |
|
Leptina |
0.25 (0.02 to 0.48) |
0.32 (0.05 to 0.59) |
<0.001 |
0.07 |
|
Adiponectin |
1.66 (0.16 to 3.17) |
2.33 (-0.27 to 4.93) |
<0.001 |
0.058 |
|
Apolipoprotein A1 |
0.09 (-0.08 to 0.26) |
0.19 (-0.01 to 0.39) |
0.004 |
0.45 |
|
Apolipoprotein B |
-0.06 (-0.16 to 0.03) |
0.07 (-0.04 to 0.18) |
0.59 |
0.33 |
|
ApoB/ApoA1 |
0.09 (-0.19 to 0.00) |
-0.01 (-0.12 to 0.10) |
0.023 |
0.56 |
|
P1NPa |
-0.02 (-0.030 to 0.25) |
-0.29 (-0.61 to 0.03) |
0.004 |
0.82 |
|
CTX1a |
-0.25 (-0.64 to 0.14) |
-0.47 (-0.62 to 0.28) |
<0.001 |
0.11 |
|
1CTPa |
-0.05 (-0.27 to 0.16) |
-0.21 (-0.46 to 0.04) |
<0.001 |
0.76 |
|
P1NP/CTX-1a |
0.23 (-0.04 to 0.49) |
-0.10 (-0.41 to 0.21) |
0.023 |
0.08 |
|
P1NP/1CTPa |
0.03 (-0.28 to 0.34) |
-0.08 (-0.44 to 0.28) |
0.45 |
0.56 |
|
IGF-1a |
0.06 (-0.07 to 0.18) |
-0.02 (-0.17 to 0.13) |
0.050 |
0.08 |
|
IGF-1 SD score |
0.32 (-0.14 to 0.78) |
0.02 (-0.52 to 0.56) |
0.003 |
0.12 |
|
|
||||
|
Data presented as mean (95% confidence interval). aArithmetic mean. Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; apo, apolipoprotein; P1NP, procollagen type I N-terminal propeptide; CTX-1, C-terminal telopeptide of type I collagen; 1CTP, C-terminal propeptide of type I collagen; IGF-1, insulin-like growth factor-1; SD, standard deviation. Changes between 3 and 12 months and patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant. |
||||
|
Engvall et al. Arthritis Research & Therapy 2010 12:R197 doi:10.1186/ar3169 |
||||
